{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:23Z","timestamp":1793317583598,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To accurately assess disease progression after Stereotactic Ablative Radiotherapy (SABR) of early-stage Non-Small Cell Lung Cancer (NSCLC), a combined predictive model based on pre-treatment CT radiomics features and clinical factors was established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study retrospectively analyzed the data of 96 patients with early-stage NSCLC treated with SABR. Clinical factors included general information (e.g. gender, age, KPS, Charlson score, lung function, smoking status), pre-treatment lesion status (e.g. diameter, location, pathological type, T stage), radiation parameters (biological effective dose, BED), the type of peritumoral radiation-induced lung injury (RILI). Independent risk factors were screened by logistic regression analysis. Radiomics features were extracted from pre-treatment CT. The minimum Redundancy Maximum Relevance (mRMR) and the Least Absolute Shrinkage and Selection Operator (LASSO) were adopted for the dimensionality reduction and feature selection. According to the weight coefficient of the features, the Radscore was calculated, and the radiomics model was constructed. Multiple logistic regression analysis was applied to establish the combined model based on radiomics features and clinical factors. Receiver Operating Characteristic (ROC) curve, DeLong test, Hosmer-Lemeshow test, and Decision Curve Analysis (DCA) were used to evaluate the model\u2019s diagnostic efficiency and clinical practicability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>With the median follow-up of 59.1 months, 29 patients developed progression and 67 remained good controlled within two years. Among the clinical factors, the type of peritumoral RILI was the only independent risk factor for progression (<jats:italic>P<\/jats:italic>&amp;lt; 0.05). Eleven features were selected from 1781 features to construct a radiomics model. For predicting disease progression after SABR, the Area Under the Curve (AUC) of training and validation cohorts in the radiomics model was 0.88 (95%CI 0.80-0.96) and 0.80 (95%CI 0.62-0.98), and AUC of training and validation cohorts in the combined model were 0.88 (95%CI 0.81-0.96) and 0.81 (95%CI 0.62-0.99). Both the radiomics and the combined models have good prediction efficiency in the training and validation cohorts. Still, DeLong test shows that there is no difference between them.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Compared with the clinical model, the radiomics model and the combined model can better predict the disease progression of early-stage NSCLC after SABR, which might contribute to individualized follow-up plans and treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.967360","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T10:40:23Z","timestamp":1659436823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Hong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuezhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongling","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinshi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1378","article-title":"Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Scott","year":"2007","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.12.050","article-title":"No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer: an analysis of RTOG 0236","volume":"88","author":"Stanic","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.05.055","article-title":"Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis","volume":"90","author":"Zheng","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12352","article-title":"Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis","volume":"7","author":"Ma","year":"2016","journal-title":"Thorac Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a retrospective analysis","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-152","article-title":"Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer","volume":"7","author":"Chang","year":"2012","journal-title":"Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318260e00d","article-title":"A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy","volume":"7","author":"Grills","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.5681","article-title":"Outcome in a prospective phase II trial of medically inoperable stageInon-small-cell lung cancer patients treated with stereotactic body radiotherapy","volume":"27","author":"Baumann","year":"2009","journal-title":"Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.155","article-title":"Outcomes after stereotactic lung radiotherapy or wedge resection for stage Inon-small-cell lung cancer","volume":"28","author":"Grills","year":"2010","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092173","article-title":"Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: A systematic review","volume":"20","author":"Chicas-Sett","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx034","article-title":"Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology","volume":"28","author":"Limkin","year":"2017","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mp.13551","article-title":"Multi-subtype classification model for non-small cell lung cancer based on radiomics: SLS model","volume":"46","author":"Liu","year":"2019","journal-title":"Med Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0999","article-title":"Radiomic detection of EGFR mutations in NSCLC","volume":"81","author":"Rossi","year":"2021","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.radonc.2019.03.032","article-title":"Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence","volume":"136","author":"van Timmeren","year":"2019","journal-title":"Radiother Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/mp.14104","article-title":"Homology-based radiomic features for prediction of the prognosis of lung cancer based on CT-based radiomics","volume":"47","author":"Kadoya","year":"2020","journal-title":"Med Phys"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ijrobp.2014.05.135","article-title":"Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer","volume":"90","author":"Timmerman","year":"2014","journal-title":"Int J RadiatOncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1623\u20431631","DOI":"10.1002\/cncr.20539","article-title":"Stereotactic hypofractionated high\u2043dose irradiation for stage I non-small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study","volume":"101","author":"Onishi","year":"2004","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"90\u20139","DOI":"10.1016\/j.ijrobp.2019.09.037","article-title":"Predicting 5\u2013year progression and survival outcomes for early stage non\u2043small cell lung cancer treated with stereotactic ablative radiation therapy: development and validation of robust prognostic nomograms","volume":"106","author":"Kang","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","first-page":"127\u201333","DOI":"10.1016\/j.lungcan.2018.12.022","article-title":"Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: comparing survival outcomes in adenocarcinoma and squamous cell carcinoma","volume":"128","author":"Abel","year":"2019","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.02.032","article-title":"Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques","volume":"80","author":"Palma","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318219aac5","article-title":"Radiological changes after stereotactic radiotherapy for stage I lung cancer","volume":"6","author":"Dahele","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e318287bd7f","article-title":"Tumor volume change with stereotactic body radiotherapy (SBRT) for early-stage lung cancer: Evaluating the potential for adaptive SBRT","volume":"38","author":"Bhatt","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.746785","article-title":"CT appearance pattern after stereotactic body radiation therapy predicts outcomes in early-stage non-Small-Cell lung cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.12.018","article-title":"Radiographic changes after lung stereotactic ablative radiotherapy (SABR) \u2013 can we distinguish recurrence from fibrosis? a systematic review of the literature","volume":"102","author":"Huang","year":"2012","journal-title":"Radiother Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-009-0415-3","article-title":"Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma","volume":"28","author":"Kato","year":"2010","journal-title":"Jpn J Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2014.12.005","article-title":"Computed tomographic features predictive of local recurrence in patients with early stage lung cancer treated with stereotactic body radiation therapy","volume":"39","author":"Halpenny","year":"2015","journal-title":"Clin Imaging"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2017.05.071","article-title":"Beyond imaging: The promise of radiomics","volume":"38","author":"Avanzo","year":"2017","journal-title":"Phys Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2021.106609","article-title":"Interpretation of radiomics features\u2013a pictorial review","volume":"215","author":"Abbasian Ardakani","year":"2022","journal-title":"Comput Methods Prog BioMed"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.11.216","article-title":"Support vector machine-based prediction of local tumor control after stereotactic body radiation therapy for early-stage non-small cell lung cancer","volume":"88","author":"Klement","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B33","doi-asserted-by":"publisher","first-page":"025007","DOI":"10.1088\/1361-6560\/aaf5a5","article-title":"Association of pre-treatment radiomics features with lung cancer recurrence following stereotactic body radiation therapy","volume":"64","author":"Lafata","year":"2019","journal-title":"Phys Med Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.819047","article-title":"A combined model to improve the prediction of local control for lung cancer patients undergoing stereotactic body radiotherapy based on radiomic signature plus clinical and dosimetric parameters","volume":"11","author":"Luo","year":"2021","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/mp.12309","article-title":"Imaging features from pretreatment CT scans are associated with clinical outcomes in non-small-cell lung cancer patients treated with stereotactic body radiotherapy","volume":"44","author":"Li","year":"2017","journal-title":"Med Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.967360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T10:40:24Z","timestamp":1659436824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.967360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":35,"alternative-id":["10.3389\/fonc.2022.967360"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.967360","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"article-number":"967360"}}